Roche says Avastin approved in U.S. for type of ovarian cancer

[November 17, 2014]  ZURICH (Reuters) - Roche said on Monday that the U.S. health regulator approved its Avastin drug as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy.

Avastin, which is already approved in Europe to treat advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer, was Roche's biggest seller last year with sales of 6.25 billion Swiss francs (6.53 billion US dollar).

(Reporting By Katharina Bart; Editing by Himani Sarkar)

[© 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.